Metoprolol succinate extended release/hydrochlorothiazide combination tablets.
Lowering elevated blood pressure (BP) with drug therapy reduces the risk for catastrophic fatal and nonfatal cardiovascular events such as stroke and myocardial infarction. Given the heterogeneity of hypertension as a disease, the marked variability in an individual patient's BP response, and low response rates with monotherapy, expert groups such as the Joint National Committee (JNC) emphasize the value of combination antihypertensive regimens, noting that combinations, usually of different classes, have additive antihypertensive effects. Metoprolol succinate extended-release tablet is a beta-1 (cardio-selective) adrenoceptor-blocking agent formulated to provide controlled and predictable release of metoprolol. Hydrochlorothiazide (HCT) is a well-established diuretic and antihypertensive agent, which promotes natruresis by acting on the distal renal tubule. The pharmacokinetics, efficacy, and safety/tolerability of the antihypertensive combination tablet, metoprolol extended release hydrochlorothiazide, essentially reflect the well-described independent characteristics of each of the component agents. Not only is the combination product more effective than monotherapy with the individual components but the combination product allows a low-dose multidrug regimen as an alternative to high-dose monotherapy, thereby, minimizing the likelihood of dose-related side-effects.
Hainer
James W
JW
AstraZeneca, Wilmington, DE 19803, USA. james.hainer@astrazeneca.com
Sugg
Jennifer
J
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006801:Humans; D006852:Hydrochlorothiazide / Q000494:pharmacology* / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D008790:Metoprolol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006852:Hydrochlorothiazide; D008790:Metoprolol
Lancet. 1999 Nov 20;354(9192):1751-6
10577635
Circulation. 2006 Jan 17;113(2):213-21
16391156
JAMA. 2002 Dec 18;288(23):2981-97
12479763
JAMA. 2003 May 21;289(19):2560-72
12748199
JAMA. 2003 May 21;289(19):2534-44
12759325
J Hypertens. 2003 Jun;21(6):1011-53
12777938
JAMA. 2003 Jul 9;290(2):199-206
12851274
J Hypertens. 2003 Nov;21(11):1983-92
14597836
Lancet. 2003 Nov 8;362(9395):1527-35
14615107
Clin Pharmacol Ther. 1976 May;19(5 Pt 1):531-7
1277708
Br J Clin Pharmacol. 1979 Jun;7(6):563-7
465277
Med Welt. 1981 Jun 5;32(23):910-4
7253898
Curr Med Res Opin. 1981;7(8):536-42
7307545
J Chronic Dis. 1982;35(3):179-82
6120945
Lancet. 1985 Jan 19;1(8421):123-6
2857210
JAMA. 1986 Mar 14;255(10):1304-10
3511308
Arch Intern Med. 1988 Apr;148(4):803-5
3281620
N Engl J Med. 2006 Apr 20;354(16):1685-97
16537662
J Clin Hypertens (Greenwich). 2006 May;8(5):336-43
16687942
Am J Hypertens. 2006 Dec;19(12):1217-25
17161766
Eur J Clin Pharmacol. 1988;33 Suppl:S3-7
3371391
J Clin Pharmacol. 1990 Feb;30(2 Suppl):S2-16
2179280
J Clin Pharmacol. 1990 Feb;30(2 Suppl):S39-45
2312778
Lancet. 1991 Nov 23;338(8778):1281-5
1682683
J Am Geriatr Soc. 1992 Apr;40(4):354-8
1556363
Drugs. 1992 Mar;43(3):382-414
1374320
J Hum Hypertens. 1994 Apr;8(4):257-63
7912734
JAMA. 2004 Nov 10;292(18):2227-36
15536109
J Hypertens. 2004 Dec;22(12):2379-86
15614033
J Clin Hypertens (Greenwich). 2006 Jan;8(1 Suppl 1):4-11
16415635
Heart Dis. 2000 Nov-Dec;2(6):392-9
11728289